AML - Keynote - Latest updates on Standard Therapies and Investigational Therapies, MRD in AML, HTC and Non-HCT

Play All
23:37

KU ASH 2018 Review: Current Updates in Hematologic Diseases

ASH 2018 AML: Deciding Between Standard vs Investigational Therapies & Problems in Evaluating New Therapies, MRD and HCT

FEATURING Elihu H. Estey
  • 571 views
  • March 19, 2019
05:54

KU ASH 2018 Review: Current Updates in Hematologic Diseases

ASH December 2018 - MRD in AML - What is the Benefit / Risk Ratio Related to HCT?

FEATURING Elihu H. Estey
  • 197 views
  • March 19, 2019
06:26

KU ASH 2018 Review: Current Updates in Hematologic Diseases

ASH December 2018 - AML - Allogeneic Hematopoietic Cell Transplantation (HCT) Vs. Non-HCT Consolidation Therapies

FEATURING Elihu H. Estey
  • 42 views
  • March 19, 2019
14:49

KU ASH 2018 Review: Current Updates in Hematologic Diseases

ASH 2018 AML Challenges in Evaluating New Therapies: Understanding the Recent FDA Approvals

FEATURING Elihu H. Estey
  • 181 views
  • March 19, 2019